Swiss Atrial Fibrillation Pulmonary Vein Isolation Registry

NCT ID: NCT03718364

Last Updated: 2025-02-18

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

3000 participants

Study Classification

OBSERVATIONAL

Study Start Date

2010-07-01

Study Completion Date

2035-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Registry of patients with atrial fibrillation undergoing catheter-based ablation of atrial fibrillation (pulmonary vein isolation) to determine long-term success rates of catheter-based ablation of atrial fibrillation (pulmonary vein isolation) and to evaluate factors associated with long-term success of catheter-based ablation of atrial fibrillation (pulmonary vein isolation).

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Catheter-based Ablation of Atrial Fibrillation

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

catheter-based ablation of atrial fibrillation (pulmonary vein isolation)

catheter-based ablation of atrial fibrillation (pulmonary vein isolation)

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* patients undergoing catheter-based ablation of atrial fibrillation (pulmonary vein isolation)

Exclusion Criteria

* Patients not able or willing to participate in this study
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University Hospital, Basel, Switzerland

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Michael Kuehne, MD

Role: PRINCIPAL_INVESTIGATOR

Cardiology/Electrophysiology, University Hospital Basel

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Cardiology/Electrophysiology, University Hospital Basel

Basel, , Switzerland

Site Status RECRUITING

University Hospital Bern

Bern, , Switzerland

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Switzerland

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Michael Kuehne, MD

Role: CONTACT

+41 61 328 74 71

Gian Voellmin, MSc

Role: CONTACT

+41 61 556 52 96

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Michael Kuehne, MD

Role: primary

+41 61 328 74 71

Hildegard Tanner, Prof. Dr. med.

Role: primary

References

Explore related publications, articles, or registry entries linked to this study.

Hennings E, Aeschbacher S, Coslovsky M, Paladini RE, Meyre PB, Voellmin G, Blum L, Kastner P, Ziegler A, Conen D, Zuern CS, Krisai P, Badertscher P, Sticherling C, Osswald S, Knecht S, Kuhne M. Association of bone morphogenetic protein 10 and recurrent atrial fibrillation after catheter ablation. Europace. 2023 Jun 2;25(6):euad149. doi: 10.1093/europace/euad149.

Reference Type DERIVED
PMID: 37314197 (View on PubMed)

Meyre PB, Sticherling C, Spies F, Aeschbacher S, Blum S, Voellmin G, Madaffari A, Conen D, Osswald S, Kuhne M, Knecht S. C-reactive protein for prediction of atrial fibrillation recurrence after catheter ablation. BMC Cardiovasc Disord. 2020 Sep 29;20(1):427. doi: 10.1186/s12872-020-01711-x.

Reference Type DERIVED
PMID: 32993521 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2018-00226; me18Kuehne2

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

The PIFPAF-PFA Study
NCT05986526 ACTIVE_NOT_RECRUITING NA